-
Je něco špatně v tomto záznamu ?
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group
SP. Gampenrieder, V. Dezentjé, M. Lambertini, A. de Nonneville, M. Marhold, F. Le Du, A. Cortés Salgado, D. Alpuim Costa, M. Vaz Batista, N. Chic Ruché, C. Tinchon, A. Petzer, E. Blondeaux, L. Del Mastro, G. Targato, F. Bertucci, A. Gonçalves, F....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu multicentrická studie, časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2016
PubMed Central
od 2016
Europe PubMed Central
od 2016
Open Access Digital Library
od 2016-01-01
Elsevier Open Access Journals
od 2016
ROAD: Directory of Open Access Scholarly Resources
od 2016
- MeSH
- lidé MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- triple-negativní karcinom prsu * farmakoterapie metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC. PATIENTS AND METHODS: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ERBB2 gene amplification. Survival probabilities were calculated by the Kaplan-Meier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models. RESULTS: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265; 29.8%) and primary tumors (n = 425; 33.4%; P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00; 95% CI 0.83-1.19; P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95; 95% CI 0.79-1.13; P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89; 95% CI 0.69-1.17; P = 0.414). CONCLUSIONS: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS.
Cancer Cluster Salzburg Salzburg Austria
Centro de Medicina Subaquática e Hiperbárica Marinha Portuguesa Lisbon Portugal
Département d'oncologie médicale Centre Eugène Marquis Rennes France
Department for Haemato Oncology LKH Hochsteiermark Leoben Leoben Austria
Department of Medical Oncology Hospital Clínic Barcelona Barcelona Spain
Department of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands
Department of Medicine 1 Division of Oncology Medical University of Vienna Vienna Austria
Dipartimento di Oncologia Ospedale Santa Maria della Misericordia di Udine Udine Italy
Faculdade de Medicina Universidade do Porto Oporto Portugal
Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Haematology and Oncology Department CUF Oncologia Lisbon Portugal
Institute of Computer Science Czech Academy of Sciences Praha Czech Republic
Medical Oncology Department Hospital Universitario Ramón y Cajal Madrid Spain
NOVA Medical School Lisbon Portugal
Oncology Department Hospital Professor Doutor Fernando Fonseca Amadora Portugal
Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials Salzburg Austria
U O Epidemiology Unit IRCCS Ospedale Policlinico San Martino Genova Genova Italy
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004333
- 003
- CZ-PrNML
- 005
- 20230425141310.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.esmoop.2022.100747 $2 doi
- 035 __
- $a (PubMed)36563519
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Gampenrieder, S P $u Salzburg Cancer Research Institute- Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria
- 245 10
- $a Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group / $c SP. Gampenrieder, V. Dezentjé, M. Lambertini, A. de Nonneville, M. Marhold, F. Le Du, A. Cortés Salgado, D. Alpuim Costa, M. Vaz Batista, N. Chic Ruché, C. Tinchon, A. Petzer, E. Blondeaux, L. Del Mastro, G. Targato, F. Bertucci, A. Gonçalves, F. Viret, R. Bartsch, C. Mannsbart, A. Deleuze, L. Robert, C. Saavedra Serrano, M. Gion Cortés, M. Sampaio-Alves, M. Vitorino, L. Pecen, C. Singer, N. Harbeck, G. Rinnerthaler, R. Greil, AGMT Study Group
- 520 9_
- $a BACKGROUND: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC. PATIENTS AND METHODS: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ERBB2 gene amplification. Survival probabilities were calculated by the Kaplan-Meier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models. RESULTS: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265; 29.8%) and primary tumors (n = 425; 33.4%; P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00; 95% CI 0.83-1.19; P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95; 95% CI 0.79-1.13; P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89; 95% CI 0.69-1.17; P = 0.414). CONCLUSIONS: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a triple-negativní karcinom prsu $x farmakoterapie $x metabolismus $7 D064726
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a prognóza $7 D011379
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Dezentjé, V $u Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
- 700 1_
- $a Lambertini, M $u Medical Oncology Department, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino Genova, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, Università di Genova, Genova, Italy
- 700 1_
- $a de Nonneville, A $u Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France
- 700 1_
- $a Marhold, M $u Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Le Du, F $u Département d'oncologie médicale, Centre Eugène-Marquis, Rennes, France
- 700 1_
- $a Cortés Salgado, A $u Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Alpuim Costa, D $u Haematology and Oncology Department, CUF Oncologia, Lisbon, Portugal; NOVA Medical School, (NMS), Faculdade de Ciências Médicas (FCM), Lisbon, Portugal; Centro de Medicina Subaquática e Hiperbárica (CMSH), Marinha Portuguesa, Lisbon, Portugal
- 700 1_
- $a Vaz Batista, M $u Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal
- 700 1_
- $a Chic Ruché, N $u Department of Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain
- 700 1_
- $a Tinchon, C $u Department for Haemato-Oncology, LKH Hochsteiermark-Leoben, Leoben, Austria
- 700 1_
- $a Petzer, A $u Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Barmherzige Schwestern-Elisabethinen, Linz, Austria
- 700 1_
- $a Blondeaux, E $u U.O. Epidemiology Unit, IRCCS Ospedale Policlinico San Martino Genova, Genova, Italy
- 700 1_
- $a Del Mastro, L $u Medical Oncology Department, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino Genova, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, Università di Genova, Genova, Italy
- 700 1_
- $a Targato, G $u Dipartimento di Oncologia, Ospedale Santa Maria della Misericordia di Udine, Udine, Italy
- 700 1_
- $a Bertucci, F $u Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France
- 700 1_
- $a Gonçalves, A $u Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France
- 700 1_
- $a Viret, F $u Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France
- 700 1_
- $a Bartsch, R $u Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Mannsbart, C $u Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Deleuze, A $u Département d'oncologie médicale, Centre Eugène-Marquis, Rennes, France
- 700 1_
- $a Robert, L $u Département d'oncologie médicale, Centre Eugène-Marquis, Rennes, France
- 700 1_
- $a Saavedra Serrano, C $u Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Gion Cortés, M $u Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
- 700 1_
- $a Sampaio-Alves, M $u Faculdade de Medicina, Universidade do Porto (FMUP), Oporto, Portugal
- 700 1_
- $a Vitorino, M $u Oncology Department, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal
- 700 1_
- $a Pecen, L $u Institute of Computer Science, Czech Academy of Sciences, Praha, Czech Republic; Faculty of Medicine in Pilsen - Charles University, Pilsen, Czech Republic
- 700 1_
- $a Singer, C $u Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Harbeck, N $u Breast Center, Department of Gynecology and Obstetrics, Comprehensive Cancer Center of the Ludwig-Maximilians-University, Munich, Germany
- 700 1_
- $a Rinnerthaler, G $u Salzburg Cancer Research Institute- Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria
- 700 1_
- $a Greil, R $u Salzburg Cancer Research Institute- Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria; IIIrd Medical Department with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria. Electronic address: r.greil@salk.at
- 710 2_
- $a AGMT Study Group
- 773 0_
- $w MED00196632 $t ESMO open $x 2059-7029 $g Roč. 8, č. 1 (2023), s. 100747
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36563519 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141306 $b ABA008
- 999 __
- $a ok $b bmc $g 1924798 $s 1190542
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 8 $c 1 $d 100747 $e 20221221 $i 2059-7029 $m ESMO open $n ESMO Open $x MED00196632
- LZP __
- $a Pubmed-20230418
